Related references
Note: Only part of the references are listed.Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma
Junichi Kiyasu et al.
BLOOD (2015)
FoxP3+ and IL-17+ cells are correlated with improved prognosis in cervical adenocarcinoma
Simone Punt et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Immune Checkpoint Modulation for Non-Small Cell Lung Cancer
Jean-Charles Soria et al.
CLINICAL CANCER RESEARCH (2015)
PD-L1 expression in small cell neuroendocrine carcinomas
Anne M. Schultheis et al.
EUROPEAN JOURNAL OF CANCER (2015)
A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G
Edgardo D. Carosella et al.
EUROPEAN UROLOGY (2015)
Evaluation of melanoma antigen gene A3 expression in drug resistance of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced nonsmall cell lung cancer treatment
Ju Jin et al.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS (2015)
The tumor area occupied by Tbet plus cells in deeply invading cervical cancer predicts clinical outcome
Arko Gorter et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma
Wendy A. Cooper et al.
LUNG CANCER (2015)
Prognostic Significance of Programmed Cell Death 1 (PD-1) or PD-1 Ligand 1 (PD-L1) Expression in Epithelial-Originated Cancer A Meta-Analysis
Yaxiong Zhang et al.
MEDICINE (2015)
Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers
Louisa Mezache et al.
MODERN PATHOLOGY (2015)
Correlations between immune response and vascularization qRT-PCR gene expression clusters in squamous cervical cancer
Simone Punt et al.
MOLECULAR CANCER (2015)
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel et al.
MOLECULAR CANCER THERAPEUTICS (2015)
The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment
Gregory K. Pennock et al.
ONCOLOGIST (2015)
Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma
Patcharee Ritprajak et al.
ORAL ONCOLOGY (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
High levels of soluble MICA are significantly related to increased disease-free and disease-specific survival in patients with cervical adenocarcinoma
S. Samuels et al.
TISSUE ANTIGENS (2015)
Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma
Marcella Callea et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Characterization of the in vivo immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma
I. Chevolet et al.
ONCOIMMUNOLOGY (2015)
PD-L1 and Survival in Solid Tumors: A Meta-Analysis
Pin Wu et al.
PLOS ONE (2015)
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
Luisa Carbognin et al.
PLOS ONE (2015)
Precise Classification of Cervical Carcinomas Combined with Somatic Mutation Profiling Contributes to Predicting Disease Outcome
Vivian M. Spaans et al.
PLOS ONE (2015)
High and Interrelated Rates of PD-L1(+)CD14(+) Antigen-Presenting Cells and Regulatory T Cells Mark the Microenvironment of Metastatic Lymph Nodes from Patients with Cervical Cancer
A. Marijne Heeren et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Programmed death ligand-1 expression in non-small cell lung cancer
Vamsidhar Velcheti et al.
LABORATORY INVESTIGATION (2014)
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Thomas Powles et al.
NATURE (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
PD-L1 Expression in Clear Cell Renal Cell Carcinoma: An Analysis of Nephrectomy and Sites of Metastases
L. B. Jilaveanu et al.
JOURNAL OF CANCER (2014)
Oncogenic Mutations in Cervical Cancer Genomic Differences Between Adenocarcinomas and Squamous Cell Carcinomas of the Cervix
Alexi A. Wright et al.
CANCER (2013)
Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma
Sofia Lyford-Pike et al.
CANCER RESEARCH (2013)
Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia
Wen Yang et al.
IMMUNOLOGY (2013)
Dendritic cell plasticity in tumor-conditioned skin: CD14(+) cells at the cross-roads of immune activation and suppression
Rieneke van de Ven et al.
FRONTIERS IN IMMUNOLOGY (2013)
Functional characterization of a STAT3-dependent dendritic cell-derived CD14+ cell population arising upon IL-10-driven maturation
Jelle J. Lindenberg et al.
ONCOIMMUNOLOGY (2013)
Role of IL-12p40 in cervical carcinoma
H. J. M. A. A. Zijlmans et al.
BRITISH JOURNAL OF CANCER (2012)
Susceptibility to cervical cancer: An overview
Antonio Carlos de Freitas et al.
GYNECOLOGIC ONCOLOGY (2012)
HLA-E expression in cervical adenocarcinomas: association with improved long-term survival
Vivian M. Spaans et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
Janis M. Taube et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Characterization of four conventional dendritic cell subsets in human skin-draining lymph nodes in relation to T-cell activation
Rieneke van de Ven et al.
BLOOD (2011)
Prognostic Model for Survival in Patients With Early Stage Cervical Cancer
Petra Biewenga et al.
CANCER (2011)
M2 Macrophages Induced by Prostaglandin E2 and IL-6 from Cervical Carcinoma Are Switched to Activated M1 Macrophages by CD4+ Th1 Cells
Moniek Heusinkveld et al.
JOURNAL OF IMMUNOLOGY (2011)
High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation
Chuan-Yong Mu et al.
MEDICAL ONCOLOGY (2011)
Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+T-Cell Infiltration and Survival of Patients with Cervical Carcinoma
Rezaul Karim et al.
CLINICAL CANCER RESEARCH (2009)
Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio:: Which variable determines survival of cervical cancer patients?
Ekaterina S. Jordanova et al.
CLINICAL CANCER RESEARCH (2008)
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up
RH Thompson et al.
CANCER RESEARCH (2006)
The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: Correlation with important high-risk prognostic factors
Hazem Ghebeh et al.
NEOPLASIA (2006)
Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance
Changping Wu et al.
ACTA HISTOCHEMICA (2006)
Radical hysterectomy for stage IIB cervical cancer: a review
P Suprasert et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2005)
B7-h1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression
J Konishi et al.
CLINICAL CANCER RESEARCH (2004)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States - A 24-year population-based study
HO Smith et al.
GYNECOLOGIC ONCOLOGY (2000)
Share Paper
